摘要
目的 探讨 2型糖尿病患者血浆纤溶酶原激活物抑制因子 - 1(PAI - 1)基因启动区 4G/5G多态性及与并发冠心病的关系。方法 118名 2型糖尿病患者 ,按有无冠心病分为两组。未合并冠心病组 80例 ,合并冠心病组38例。应用PCR扩增PAI 1基因启动区片段 ,γ32P末端标记 2个序列特异性寡核苷酸 (ASO)进行点杂交 ,比较基因型在两组糖尿病人群中的分布及与血浆PAI 1活性的关系。结果 (1)合并冠心病的 2型糖尿病患者较未合并冠心病组 4G基因型的频率升高 ,但未达统计学意义 (P >0 .0 5 ) ;(2 )两组的血浆PAI 1活性差异明显 (10 .32± 2 .6 5vs8.87± 3 .2 4)kU/L ,P <0 .0 5 ;(3)两组的血TG水平差异明显 (1.99± 1.0 4vs 1.5 6± 0 .72 )mmol/L ,P <0 .0 5 ;(4)两组的空腹胰岛素水平差异明显 (14.6± 5 .8vs 11.2± 4.3)kU/L ,P <0 .0 5 ;(5 )在 4G/4G基因型患者中血浆PAI 1活性与TG明显相关 (r=0 .5 7,P <0 .0 5 )。结论 PAI 1活性升高及PAI 1基因启动区
Objective To investigate the relationship of plasminogen activator inhibitor 1(PAI?1) gene 4G/5G polymorphism with PAI?1 activity in type 2 diabetes with and without CHD. Methods 118 type 2 diabetes were divided into two groups with or without CHD based on Minnesota standard diagnosis. After amplification with polymerase chain reaction, the fragment of promoter region of PAI?1 gene was hybridized with allele specific oligonucleotide(ASO) labeled with γ32P.Results The frequency of 4G/5G genotype increased and 5G/5G genotype decreased in the group with CHD as compared with those without CHD but there was no significance ( P >0.05). PAI?1 activity level (10.32±2.65 vs 8.87 ±3.24, P< 0.05), TG level ( 1.99±1.04 vs 1.56±0.72, P< 0.05 ) and fasting insulin level ( 14.6±5.8 vs 11.2±4.3, P< 0.05 ) were higher in the group with CHD. PAI?1 was significantly correlated with TG in 4G/4G genotype patients ( r =0.57, P< 0.05 ). Conclusion Elevated levels of PAI?1 and 4G/4G PAI?1 promoter genotype are risk factors for the development of CHD in type 2 diabetic patients.
出处
《同济大学学报（医学版）》
CAS
2001年第4期16-19,共4页
Journal of Tongji University(Medical Science)
基金
上海铁路局科技基金资助项目 (J96Z0 14 )
